<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084980</url>
  </required_header>
  <id_info>
    <org_study_id>MCNS001</org_study_id>
    <nct_id>NCT01084980</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome</brief_title>
  <acronym>MCNS</acronym>
  <official_title>A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that tacrolimus reduces the proteinuria in adult patient with&#xD;
      minimal change nephritic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot study for comparative clinical trial on the therapeutic effect of tacrolimus (Prograf&#xD;
      cap®) in adult patient with minimal change nephritic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission of proteinuria</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to remission, relapse rate, response failure rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Minimal Change Disease</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  from 18yrs to 80 yrs , man and women&#xD;
&#xD;
          -  Minimal change disease is diagnosed by kidney biopsy&#xD;
&#xD;
          -  On screening, the patient shows that the level of urine protein/creatinine ratio is&#xD;
             over 3.0&#xD;
&#xD;
          -  On screening, the patient shows that the serum albumin is below 3.0g/dL&#xD;
&#xD;
          -  the patient sign on the concent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the patient have experience to take tacrolimus or cyclosporin for 1 month&#xD;
&#xD;
          -  If it is the relapse of the nephrotic syndrome, before relapse, the maintenance dose&#xD;
             of steroid is over 0.3 mg/kg/day&#xD;
&#xD;
          -  steroid dependent or steroid resistant or frequent relapse case&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  pregnancy or anticipate pregnancy with 6 month&#xD;
&#xD;
          -  hypersensitivity to tacrolimus or macrolide&#xD;
&#xD;
          -  acute hepatitis or the level of AST or ALT is over 2 times of normal range or the&#xD;
             level of bilirubin is over 2.0 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>August 12, 2011</last_update_submitted>
  <last_update_submitted_qc>August 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suhnggwon Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>minimal change disease</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

